{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"8.0","value":"2.8"},{"groupId":"OG001","lowerLimit":"0.7","upperLimit":"6.4","value":"2.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"158"}],"units":"Participants"}],"description":"The percentage of participants who moved on to stem cell transplant was summarized.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG000","title":"Main Cohort"},{"description":"Participants in the Main Cohort received ABT-199 tablets once daily (QD) orally for up to 79 months,and those in the Safety Expansion Cohort received ABT-199 tablets once daily (QD) orally for up to 68 months. For both groups, the starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG001","title":"All Treated Participants"}],"paramType":"NUMBER","populationDescription":"All treated participants with available data","reportingStatus":"POSTED","timeFrame":"Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up","title":"Percentage of Participants Who Moved on to Stem Cell Transplant","type":"SECONDARY","unitOfMeasure":"percentage of participants"}